Skip main navigation
Home / Healthcare & Medicine / Pharmacy / Pharmacokinetics: Drug Dosing in Renal Disease / Fluid and Electrolytes imbalance : Hyperphosphatemia & hypocalcemia

Fluid and Electrolytes imbalance : Hyperphosphatemia & hypocalcemia

Fluid and Electrolytes imbalance : Hyperphosphatemia and hypocalcemia
View transcript
14.2
And let’s look at other electrolytes imbalance As very common we see patient with hyperphosphatemia and hypocalcemia and hypermagnesemia and along with these three issues. We will see a patient has bad bone osteodystrophy So hyperphosphatemia has actually from renal reducer renal excretion and hypocalemia is also from those patients PTH level and hypermagnesia also require our discontinued with some magnesium continent untested and for calcium a phosphorus balance, we need to always remember keep calcium concentration and the phosphate level the summation less than fifty-five milligram per deciliter. For hyperphosphatemia we can actually use some calcium carbonate or acetate, citrate And most commonly used as calcium carbonate.
99.3
So that will actually has a lots of a productivist selected we need to care for to look at those products whether or not and those superior has something else other than calcium carbonate And there are the other few newer polymer binders for phosphate. What is sevelamer? And this is a very important new phosphate binder. There there are two different salts including carbonate salts and hydrochloride salts. Using these salts, you usually need to also consider about the dosing equivalence. So there is a formula for your reference. And using this new binder, there are some ADR occurred including fecal impaction ileus or some intestinal obstruction Let’s need to carefully watch out.
173.7
And then follow me, There is another new phosphate binder and this usually need to think about those aluminum salts. And also reduce the bioavailability of ciprofloxacin and levothyroxine is very important drug in action.

In this step, Prof. Chen explains hyperphosphatemia, hypocalcemia, hypermagnesemia, and calcium and phosphorus balance.

To begin with, hyperphosphatemia is from reduced renal excretion and excessive cellular release, and hypocalcemia is from an abnormal PTH level.

For calcium and phosphorus balance, we need to keep the product of calcium concentration and the phosphate level less than 55 milligrams per deciliter.

Besides, there are other polymer binders, including Sevelamer HCL and Sevelamer carbonate. However, they may cause some ADRs, such as fecal impaction and intestinal obstruction.

Following that, there is another new phosphate binder, called Lanthanum, which dissociates into a trivalent cation with similar binding. Lanthanum will reduce the bioavailability of ciprofloxacin and levothyroxine.

Have you ever used Lanthanum in clinical practice? Please share your experience before.

Want to keep learning?

This content is taken from Taipei Medical University online course
Pharmacokinetics: Drug Dosing in Renal Disease
View Course
See other articles from this course
This article is from the online course:

Pharmacokinetics: Drug Dosing in Renal Disease

Created by
Join Now
This article is from the free online

Pharmacokinetics: Drug Dosing in Renal Disease

Created by
Join Now
FutureLearn - Learning For Life

Reach your personal and professional goals

Unlock access to hundreds of expert online courses and degrees from top universities and educators to gain accredited qualifications and professional CV-building certificates.

Join over 18 million learners to launch, switch or build upon your career, all at your own pace, across a wide range of topic areas.

Start Learning now

Register to receive updates

  • Create an account to receive our newsletter, course recommendations and promotions.

    Register for free